139 related articles for article (PubMed ID: 11283141)
1. Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases.
Carde P; Timmerman R; Mehta MP; Koprowski CD; Ford J; Tishler RB; Miles D; Miller RA; Renschler MF
J Clin Oncol; 2001 Apr; 19(7):2074-83. PubMed ID: 11283141
[TBL] [Abstract][Full Text] [Related]
2. Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points.
Mehta MP; Shapiro WR; Glantz MJ; Patchell RA; Weitzner MA; Meyers CA; Schultz CJ; Roa WH; Leibenhaut M; Ford J; Curran W; Phan S; Smith JA; Miller RA; Renschler MF
J Clin Oncol; 2002 Aug; 20(16):3445-53. PubMed ID: 12177105
[TBL] [Abstract][Full Text] [Related]
3. Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: preliminary results in brain metastases.
Viala J; Vanel D; Meingan P; Lartigau E; Carde P; Renschler M
Radiology; 1999 Sep; 212(3):755-9. PubMed ID: 10478243
[TBL] [Abstract][Full Text] [Related]
4. A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging.
Rosenthal DI; Nurenberg P; Becerra CR; Frenkel EP; Carbone DP; Lum BL; Miller R; Engel J; Young S; Miles D; Renschler MF
Clin Cancer Res; 1999 Apr; 5(4):739-45. PubMed ID: 10213207
[TBL] [Abstract][Full Text] [Related]
5. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial.
Mehta MP; Shapiro WR; Phan SC; Gervais R; Carrie C; Chabot P; Patchell RA; Glantz MJ; Recht L; Langer C; Sur RK; Roa WH; Mahe MA; Fortin A; Nieder C; Meyers CA; Smith JA; Miller RA; Renschler MF
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1069-76. PubMed ID: 18977094
[TBL] [Abstract][Full Text] [Related]
6. Safety and feasibility of motexafin gadolinium administration with whole brain radiation therapy and stereotactic radiosurgery boost in the treatment of ≤ 6 brain metastases: a multi-institutional phase II trial.
McHaffie DR; Chabot P; Dagnault A; Suh JH; Fortin MA; Chang E; Timmerman R; Souhami L; Grecula J; Nabid A; Schultz C; Werner-Wasik M; Gaspar LE; Brachman D; Mody T; Mehta MP
J Neurooncol; 2011 Nov; 105(2):301-8. PubMed ID: 21523486
[TBL] [Abstract][Full Text] [Related]
7. Results of the phase I dose-escalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme.
Ford JM; Seiferheld W; Alger JR; Wu G; Endicott TJ; Mehta M; Curran W; Phan SC
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):831-8. PubMed ID: 17560737
[TBL] [Abstract][Full Text] [Related]
8. A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118).
Knisely JP; Berkey B; Chakravarti A; Yung AW; Curran WJ; Robins HI; Movsas B; Brachman DG; Henderson RH; Mehta MP
Int J Radiat Oncol Biol Phys; 2008 May; 71(1):79-86. PubMed ID: 18164847
[TBL] [Abstract][Full Text] [Related]
9. The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trial.
Evens AM; Spies WG; Helenowski IB; Patton D; Spies S; Jovanovic BD; Miyata S; Hamilton E; Variakojis D; Chen J; Naumovski L; Rosen ST; Winter JN; Miller RA; Gordon LI
Clin Cancer Res; 2009 Oct; 15(20):6462-71. PubMed ID: 19825958
[TBL] [Abstract][Full Text] [Related]
10. Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I study.
Bradley KA; Pollack IF; Reid JM; Adamson PC; Ames MM; Vezina G; Blaney S; Ivy P; Zhou T; Krailo M; Reaman G; Mehta MP;
Neuro Oncol; 2008 Oct; 10(5):752-8. PubMed ID: 18715950
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II trial of simultaneous whole-brain irradiation and dose-escalating topotecan for brain metastases.
Kocher M; Eich HT; Semrau R; Güner SA; Müller RP
Strahlenther Onkol; 2005 Jan; 181(1):20-5. PubMed ID: 15660189
[TBL] [Abstract][Full Text] [Related]
12. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases.
Mehta MP; Rodrigus P; Terhaard CH; Rao A; Suh J; Roa W; Souhami L; Bezjak A; Leibenhaut M; Komaki R; Schultz C; Timmerman R; Curran W; Smith J; Phan SC; Miller RA; Renschler MF
J Clin Oncol; 2003 Jul; 21(13):2529-36. PubMed ID: 12829672
[TBL] [Abstract][Full Text] [Related]
13. Motexafin gadolinium: gadolinium (III) texaphyrin, gadolinium texaphyrin, Gd-Tex, GdT2B2, PCI 0120.
Drugs R D; 2004; 5(1):52-7. PubMed ID: 14725495
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer.
William WN; Zinner RG; Karp DD; Oh YW; Glisson BS; Phan SC; Stewart DJ
J Thorac Oncol; 2007 Aug; 2(8):745-50. PubMed ID: 17762342
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers.
Ramanathan RK; Fakih M; Mani S; Deutsch M; Perez RP; Ritter MA; Eiseman JL; Ivy SP; Trump DL; Belani CP; Parise RA; Potter DM; Egorin MJ
Cancer Chemother Pharmacol; 2006 Apr; 57(4):465-74. PubMed ID: 16133531
[TBL] [Abstract][Full Text] [Related]
16. Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost in Patients With Brain Oligometastases: A Phase 1 Study (ISIDE-BM-1).
Ferro M; Chiesa S; Macchia G; Cilla S; Bertini F; Frezza G; Farioli A; Cammelli S; Balducci M; Ianiro A; Angelini AL; Compagnone G; Valentini V; Deodato F; Morganti AG
Int J Radiat Oncol Biol Phys; 2017 Jan; 97(1):82-90. PubMed ID: 27843034
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of short-course accelerated whole brain radiation therapy for multiple brain metastases.
Caravatta L; Deodato F; Ferro M; Macchia G; Massaccesi M; Cilla S; Padula GD; Mignogna S; Tambaro R; Carrozza F; Flocco M; Cantore G; Scapati A; Buwenge M; Sticca G; Valentini V; Cellini N; Morganti AG
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):e463-8. PubMed ID: 22909415
[TBL] [Abstract][Full Text] [Related]
18. Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors.
Khuntia D; Mehta M
Expert Rev Anticancer Ther; 2004 Dec; 4(6):981-9. PubMed ID: 15606327
[TBL] [Abstract][Full Text] [Related]
19. Motexafin gadolinium: a redox-active tumor selective agent for the treatment of cancer.
Evens AM
Curr Opin Oncol; 2004 Nov; 16(6):576-80. PubMed ID: 15627019
[TBL] [Abstract][Full Text] [Related]
20. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial.
Meyers CA; Smith JA; Bezjak A; Mehta MP; Liebmann J; Illidge T; Kunkler I; Caudrelier JM; Eisenberg PD; Meerwaldt J; Siemers R; Carrie C; Gaspar LE; Curran W; Phan SC; Miller RA; Renschler MF
J Clin Oncol; 2004 Jan; 22(1):157-65. PubMed ID: 14701778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]